Copyright © 1998 by the European Society of Cardiology.
Beta-blockers and antithrombotic treatment for secondary prevention after acute myocardial infarction
Towards an understanding of factors influencing clinical practice
The European Secondary Prevention Study Group
accepted April 25, 1997
Aims Long-term beta-blockade reduced mortality after acute myocardial infarction by about a quarter in a series of published trials. Representative data on beta-blocker use for secondary prevention are scanty but indicate wide variations. We have analysed European practice, and sources of variation, by regional sampling of acute myo-cardial infarction patients admitted to hospital in 11 countries during the period January 1993–June 1994.
Methods and results Treatment data for 4035 representative patients were collected for the hospital phase and 6 months after discharge. A logistic regression model was developed to describe the predictors of beta-blocker use. In the 11 regional samples, 6–38% (20% overall) of patients had no recorded contraindications but were discharged without a beta-blocker. In the absence of perceived contraindications, there was a strong, independent negative association between age and odds of treatment (P<0·001), and women were less likely to be treated than men (adjusted odds ratio 0·76, 95% CI0·58–0·99). Discontinuation of beta-blocker treatment by 6 months was significantly less likely in regions where the proportion given such treatment at discharge was high. In contrast, use of antithrombotic agents in the samples was consistently high.
Conclusions There is persisting low use of beta-blocker secondary prophylaxis, particularly in the elderly and in women, not attributable to perceived contraindications or intolerance. Considerable regional variations persist despite shared trials evidence. Discharge treatment strongly influences long-term medication.
Key Words: Myocardial infarction • drug therapy • drug utilization • secondary prevention • ß-adrenoceptor antagonists
f1 Correspondence: Professor K. L. Woods, Department of Medicine and Therapeutics, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, U.K.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346. [Full Text] [PDF]
|
|
|
|
 |
|
 Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace, September 1, 2006; 8(9): 746 - 837. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Grimshaw, M. Eccles, M. Campbell, and D. Elbourne Cluster Randomized Trials of Professional and Organizational Behavior Change Interventions in Health Care Settings The ANNALS of the American Academy of Political and Social Science, May 1, 2005; 599(1): 71 - 93. [Abstract] [PDF]
|
|
|
|
|
|
G. Steinbeck, D. Andresen, J. Senges, E. Hoffmann, K. Seidl, J. Brachmann, and for the IRIS investigators as Joint Study of the G Immediate Risk-Stratification Improves Survival (IRIS): study protocol Europace, January 1, 2004; 6(5): 392 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zaugg, M. C. Schaub, T. Pasch, and D. R. Spahn Modulation of {beta}-adrenergic receptor subtype activities in perioperative medicine: mechanisms and sites of action Br. J. Anaesth., January 1, 2002; 88(1): 101 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Eccles, J. Grimshaw, N. Steen, D. Parkin, I. Purves, E. McColl, and N. Rousseau The design and analysis of a randomized controlled trial to evaluate computerized decision support in primary care: the COGENT study Fam. Pract., April 1, 2000; 17(2): 180 - 186. [Full Text] [PDF]
|
|
|
|
 |
|
 The Study Group on Diagnosis of the Working Group Increasing awareness and improving the management of heart failure in Europe: the IMPROVEMENT of HF initiative Eur J Heart Fail, June 1, 1999; 1(2): 139 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K L Woods, D Ketley, P. F Ludman, K. Hardy, and S. O'Brien Intravenous beta blockade in acute myocardial infarction BMJ, January 30, 1999; 318(7179): 328b - 328. [Full Text]
|
|
|
|
 |
|
 D. P. Zipes and H. J. J. Wellens Sudden Cardiac Death Circulation, November 24, 1998; 98(21): 2334 - 2351. [Full Text] [PDF]
|
|